Design Therapeutics (DSGN) Non-Current Assets (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Non-Current Assets of $3.1 million for Q2 2026, up 0.78% year-over-year from $3.1 million in Q2 2025, and down 8.16% on a QoQ basis from $3.4 million in Q1 2026.
Design Therapeutics (DSGN) Non-Current Assets (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Non-Current Assets for 7 years, with the latest figure at $3.1 million in Q2 2026.
- Non-Current Assets for Q2 2026 came in at $3.1 million, up 0.78% year-over-year; the trailing twelve-month figure through Jun 2026 was $11.7 million (down 24.04% YoY), and the FY2025 annual result was $2.4 million, down 40.32% from the prior year.
- Non-Current Assets declined to $3.1 million in Q2 2026, from $3.4 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $6.2 million in Q2 2022 and troughed at $2.4 million in Q4 2025.
- A 5-year average of $4.5 million and a median of $4.8 million in 2024 frame the typical range for Non-Current Assets.
- The widest annual swing landed in 2022, when Non-Current Assets surged 4830.0%; it then plunged 40.32% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $6.0 million in 2022, then decreased by 15.94% to $5.1 million in 2023, then dropped by 19.89% to $4.1 million in 2024, then plunged by 40.32% to $2.4 million in 2025, then advanced by 28.81% to $3.1 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $3.1 million in Q2 2026, $3.4 million in Q1 2026, and $2.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 3.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.12 Mn |
| Mar 31, 2026 | 3.39 Mn |
| Dec 31, 2025 | 2.42 Mn |
| Sep 30, 2025 | 2.74 Mn |
| Jun 30, 2025 | 3.09 Mn |
| Mar 31, 2025 | 3.83 Mn |
| Dec 31, 2024 | 4.05 Mn |
| Sep 30, 2024 | 4.39 Mn |
| Jun 30, 2024 | 4.74 Mn |
| Mar 31, 2024 | 4.91 Mn |
| Dec 31, 2023 | 5.06 Mn |
| Sep 30, 2023 | 5.33 Mn |
| Jun 30, 2023 | 5.59 Mn |
| Mar 31, 2023 | 5.80 Mn |
| Dec 31, 2022 | 6.02 Mn |
| Sep 30, 2022 | 6.08 Mn |
| Jun 30, 2022 | 6.21 Mn |
| Mar 31, 2022 | 4.93 Mn |
| Dec 31, 2021 | 5.12 Mn |
| Sep 30, 2021 | 5.06 Mn |